PLoS One:催产素和去甲肾上腺素水平的提高可预示过敏性鼻炎患者更高的应激水平

2018-06-13 AlexYang MedSci原创

急性应激对过敏症状的影响仍旧所知甚少。最近,有研究人员进行了临床研究,旨在探明过敏性鼻炎(AR)中,急性应激和相关调节因子的影响,并利用皮刺试验(SPT)的疹块红斑反应来作为反应的标记。研究包括了19名健康参与者和21名AR患者。研究评估了经历特里尔社会压力测试(TSST)且具有应激响应的14名过敏性鼻炎和11名健康参与者的SPT结果。研究发现,在小组水平上,应激测试前后对过敏原或者组胺的SPT结

急性应激对过敏症状的影响仍旧所知甚少。最近,有研究人员进行了临床研究,旨在探明过敏性鼻炎(AR)中,急性应激和相关调节因子的影响,并利用皮刺试验(SPT)的疹块红斑反应来作为反应的标记。

研究包括了19名健康参与者和21名AR患者。研究评估了经历特里尔社会压力测试(TSST)且具有应激响应的14名过敏性鼻炎和11名健康参与者的SPT结果。研究发现,在小组水平上,应激测试前后对过敏原或者组胺的SPT结果没有显著的差异。但是,在一些个体中,TSST后疹块红斑反应大小具有增加或者减少的差异变化,并且1名健康参与者出现了敏化症状,且与测试的任何调节因子没有关联。另外,最显著的发现是,催产素和去甲肾上腺素的水平在过敏患者中显著更高,且与TSST无关。

最后,研究人员指出,去甲肾上腺素高的基线水平意味着过敏患者更高的应激水平,并且可能受催产素逆向调控。更多的是,他们的数据表明了在易感个体中,急性应激也许对SPT的准确度有着显著的影响。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1895130, encodeId=7263189513020, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Tue Sep 25 18:59:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046977, encodeId=be1320469e751, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 24 06:59:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790222, encodeId=a8c01e90222d2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Apr 15 20:59:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284905, encodeId=3a9c128490599, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445227, encodeId=b610144522eca, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529939, encodeId=454d152993967, content=<a href='/topic/show?id=010228026b8' target=_blank style='color:#2F92EE;'>#催产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28026, encryptionId=010228026b8, topicName=催产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f1711981795, createdName=zhanfl, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323918, encodeId=bb7932391851, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Jun 13 21:02:03 CST 2018, time=2018-06-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1895130, encodeId=7263189513020, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Tue Sep 25 18:59:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046977, encodeId=be1320469e751, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 24 06:59:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790222, encodeId=a8c01e90222d2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Apr 15 20:59:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284905, encodeId=3a9c128490599, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445227, encodeId=b610144522eca, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529939, encodeId=454d152993967, content=<a href='/topic/show?id=010228026b8' target=_blank style='color:#2F92EE;'>#催产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28026, encryptionId=010228026b8, topicName=催产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f1711981795, createdName=zhanfl, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323918, encodeId=bb7932391851, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Jun 13 21:02:03 CST 2018, time=2018-06-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1895130, encodeId=7263189513020, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Tue Sep 25 18:59:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046977, encodeId=be1320469e751, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 24 06:59:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790222, encodeId=a8c01e90222d2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Apr 15 20:59:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284905, encodeId=3a9c128490599, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445227, encodeId=b610144522eca, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529939, encodeId=454d152993967, content=<a href='/topic/show?id=010228026b8' target=_blank style='color:#2F92EE;'>#催产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28026, encryptionId=010228026b8, topicName=催产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f1711981795, createdName=zhanfl, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323918, encodeId=bb7932391851, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Jun 13 21:02:03 CST 2018, time=2018-06-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1895130, encodeId=7263189513020, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Tue Sep 25 18:59:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046977, encodeId=be1320469e751, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 24 06:59:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790222, encodeId=a8c01e90222d2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Apr 15 20:59:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284905, encodeId=3a9c128490599, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445227, encodeId=b610144522eca, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529939, encodeId=454d152993967, content=<a href='/topic/show?id=010228026b8' target=_blank style='color:#2F92EE;'>#催产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28026, encryptionId=010228026b8, topicName=催产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f1711981795, createdName=zhanfl, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323918, encodeId=bb7932391851, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Jun 13 21:02:03 CST 2018, time=2018-06-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1895130, encodeId=7263189513020, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Tue Sep 25 18:59:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046977, encodeId=be1320469e751, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 24 06:59:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790222, encodeId=a8c01e90222d2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Apr 15 20:59:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284905, encodeId=3a9c128490599, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445227, encodeId=b610144522eca, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529939, encodeId=454d152993967, content=<a href='/topic/show?id=010228026b8' target=_blank style='color:#2F92EE;'>#催产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28026, encryptionId=010228026b8, topicName=催产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f1711981795, createdName=zhanfl, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323918, encodeId=bb7932391851, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Jun 13 21:02:03 CST 2018, time=2018-06-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1895130, encodeId=7263189513020, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Tue Sep 25 18:59:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046977, encodeId=be1320469e751, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 24 06:59:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790222, encodeId=a8c01e90222d2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Apr 15 20:59:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284905, encodeId=3a9c128490599, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445227, encodeId=b610144522eca, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529939, encodeId=454d152993967, content=<a href='/topic/show?id=010228026b8' target=_blank style='color:#2F92EE;'>#催产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28026, encryptionId=010228026b8, topicName=催产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f1711981795, createdName=zhanfl, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323918, encodeId=bb7932391851, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Jun 13 21:02:03 CST 2018, time=2018-06-13, status=1, ipAttribution=)]
    2018-06-15 zhanfl
  7. [GetPortalCommentsPageByObjectIdResponse(id=1895130, encodeId=7263189513020, content=<a href='/topic/show?id=ce478241e0b' target=_blank style='color:#2F92EE;'>#肾上腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82417, encryptionId=ce478241e0b, topicName=肾上腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Tue Sep 25 18:59:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046977, encodeId=be1320469e751, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 24 06:59:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790222, encodeId=a8c01e90222d2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Apr 15 20:59:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284905, encodeId=3a9c128490599, content=<a href='/topic/show?id=b67d8244123' target=_blank style='color:#2F92EE;'>#肾上腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82441, encryptionId=b67d8244123, topicName=肾上腺素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445227, encodeId=b610144522eca, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529939, encodeId=454d152993967, content=<a href='/topic/show?id=010228026b8' target=_blank style='color:#2F92EE;'>#催产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28026, encryptionId=010228026b8, topicName=催产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f1711981795, createdName=zhanfl, createdTime=Fri Jun 15 10:59:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323918, encodeId=bb7932391851, content=好文章.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Jun 13 21:02:03 CST 2018, time=2018-06-13, status=1, ipAttribution=)]
    2018-06-13 1e0f8808m18(暂无匿称)

    好文章.学习了.

    0

相关资讯

Allergy:花粉季节新的EAACI定义能够反应草和桦树花粉诱导的过敏性鼻炎症状负荷

过敏原免疫疗法(AIT)在过敏性鼻炎中的使用和它的临床试验效果依赖于花粉过敏原接触的时期的有效判断。最近,有研究人员评估了德国花粉数据资料,从而来调查对花粉季节和花粉峰值开始和结束时间的新的定义。研究人员的目的是依据现实生活数据来阐释这些定义反应草和桦树花粉诱导的过敏性鼻炎症状负荷的能力。研究人员利用来自德国柏林和勃兰登堡4个花粉检测地点的3年(2014-2016)的数据来进行季节定义、桦树和草花

Int Immunopharmacol:过敏性鼻炎患者中,IL-1R8的表达增加且其配体IL-37具有免疫调节作用

过敏性鼻炎(AR)是一种慢性气道炎症性疾病,并且是由异常的T细胞响应引起。T辅助(Th)-17细胞和Th2细胞是 CD4+ T细胞的其中一部分,并且在AR的发病机理中有作用。这些Th17和Th2细胞过度响应的抑制在治疗AR患者中非常有效,并且正在研究其持续的效应,从而为调控这些细胞的功能找到新的方法。之前的研究表明了IL-1R8和它的配体IL-37能够负调控免疫响应。最近,有研究人员在AR患者中调

Indian J Pediatr:在过敏性鼻炎中,舌下免疫治疗能够减少儿童中白介素-33的表达

最近,有研究人员在患有AR(过敏性鼻炎)的儿童中鉴定了IL-33在SLIT(舌下免疫治疗)期间的表达情况。研究包括了30名对屋尘螨(HDM)过敏的儿童并且接受SLIT治疗,另外30名儿童则接受安慰剂治疗作为对照。在SLIT期间,研究人员收集了处理组和对照组不同时间点的血清和鼻腔灌洗样本,并利用酶联免疫法(ELISA)对这些样本的白介素-33和其他细胞因子进行了评估。研究人员还制备了外周血单个核细胞

Int Arch Allergy Immunol:年轻成年人中喘息和身体质量指数与常年和季节过敏性鼻炎的相关性分析

哮喘和过敏性鼻炎(AR)的并存和与肥胖不同的相关关系已见报道。然而,很少有研究区分这两种类型的AR,即常年性(PAR)和季节性(SAR)与哮喘和肥胖之间的相关性。最近,有研究人员在日本年轻成年人中,评估了喘息与上述两种类型的AR的共存,以及身体质量指数(BMI)对这两种条件下的影响。研究发现,尽管PAR和SAR都与喘息显著相关,这两种类型的AR对喘息的影响是不同的(OR for PAR = 2.4

Pediatr Allergy Immunol:在过敏性鼻炎中,瘦蛋白/骨调素通路能够导致辅助性T细胞17类型响应的增强

之前的研究表明了辅助性T细胞17(Th17)亚型,一种明显的促炎症CD4+T细胞株系,在过敏性鼻炎中(AR)的发病机理中也许具有重要的作用。然而,在过敏性疾病中,Th17响应的调控并没有很好的进行鉴定。最近,有研究人员募集了30名AR儿童和30名健康儿童进行了相关研究。研究发现,血清瘦蛋白和OPN在AR儿童中水平的提高与血清IL-17水平相关(r=0.53, P<0.01)。在PBMCs中,

J Allergy Clin Immunol Pract:成年人中轻度哮喘的长期发展轨迹和恶化风险因子分析

大多数哮喘患者的疾病程度较轻。然而,轻度哮喘的临床过程和恶化的风险因子却没有很详细的研究。最近,有研究人员调查了轻度哮喘的长期发展轨迹和早期风险因素对虽有疾病情况的影响。研究包括了在1997年到2012年被新诊断为轻度哮喘的年龄在14岁到45岁之间的患者。研究人员利用序数逻辑回归评估了相关参数之间的关系。研究共包括了70829名伴随轻度哮喘的患者(62%为女性,平均年龄为31岁)。在10年间,8%